Literature DB >> 20001796

Critical review of prostate cancer predictive tools.

Shahrokh F Shariat1, Michael W Kattan, Andrew J Vickers, Pierre I Karakiewicz, Peter T Scardino.   

Abstract

Prostate cancer is a very complex disease, and the decision-making process requires the clinician to balance clinical benefits, life expectancy, comorbidities and potential treatment-related side effects. Accurate prediction of clinical outcomes may help in the difficult process of making decisions related to prostate cancer. In this review, we discuss attributes of predictive tools and systematically review those available for prostate cancer. Types of tools include probability formulas, look-up and propensity scoring tables, risk-class stratification prediction tools, classification and regression tree analysis, nomograms and artificial neural networks. Criteria to evaluate tools include discrimination, calibration, generalizability, level of complexity, decision analysis and ability to account for competing risks and conditional probabilities. The available predictive tools and their features, with a focus on nomograms, are described. While some tools are well-calibrated, few have been externally validated or directly compared with other tools. In addition, the clinical consequences of applying predictive tools need thorough assessment. Nevertheless, predictive tools can facilitate medical decision-making by showing patients tailored predictions of their outcomes with various alternatives. Additionally, accurate tools may improve clinical trial design.

Entities:  

Mesh:

Year:  2009        PMID: 20001796      PMCID: PMC2933457          DOI: 10.2217/fon.09.121

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  182 in total

1.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Alex Smith; Michael W Kattan; Jaya Satagopan; Victor E Reuter; Peter T Scardino; William L Gerald
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor.

Authors:  David F Penson; Gary D Grossfeld; Yu-Ping Li; James M Henning; Deborah P Lubeck; Peter R Carroll
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.

Authors:  Robert Svatek; Pierre I Karakiewicz; Michael Shulman; Jose Karam; Paul Perrotte; Elie Benaim
Journal:  Eur Urol       Date:  2006-01-06       Impact factor: 20.096

6.  Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies.

Authors:  Carsten Stephan; Henning Cammann; Axel Semjonow; Eleftherios P Diamandis; Leon F A Wymenga; Michael Lein; Pranav Sinha; Stefan A Loening; Klaus Jung
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

7.  Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening.

Authors:  Patrik Finne; Ralf Finne; Chris Bangma; Jonas Hugosson; Matti Hakama; Anssi Auvinen; Ulf-Håkan Stenman
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

8.  Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.

Authors:  Liang Wang; Hedvig Hricak; Michael W Kattan; Lawrence H Schwartz; Steven C Eberhardt; Hui-Ni Chen; Peter T Scardino
Journal:  AJR Am J Roentgenol       Date:  2006-03       Impact factor: 3.959

9.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

View more
  60 in total

1.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Authors:  Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

2.  Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Authors:  Robert B Den; Kasra Yousefi; Edouard J Trabulsi; Firas Abdollah; Voleak Choeurng; Felix Y Feng; Adam P Dicker; Costas D Lallas; Leonard G Gomella; Elai Davicioni; R Jeffrey Karnes
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Multiparametric magnetic resonance imaging versus Partin tables and the Memorial Sloan-Kettering cancer center nomogram in risk stratification of patients with prostate cancer referred to external beam radiation therapy.

Authors:  Rossano Girometti; Martina Pancot; Marco Andrea Signor; Martina Urbani; Luca Balestreri; Chiara Zuiani
Journal:  Radiol Med       Date:  2018-05-12       Impact factor: 3.469

4.  Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.

Authors:  Hebert Alberto Vargas; Oguz Akin; Amita Shukla-Dave; Jingbo Zhang; Kristen L Zakian; Junting Zheng; Kent Kanao; Debra A Goldman; Chaya S Moskowitz; Victor E Reuter; James A Eastham; Peter T Scardino; Hedvig Hricak
Journal:  Radiology       Date:  2012-09-05       Impact factor: 11.105

Review 5.  Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma.

Authors:  Evanguelos Xylinas; Luis Kluth; Sibani Mangal; Morgan Roupret; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

6.  Prostate cancer biomarker: a key field to explore.

Authors:  Jianqing Lin; Hushan Yang; William K Kelly
Journal:  Asian J Androl       Date:  2013-02-25       Impact factor: 3.285

Review 7.  Treatment of localized prostate cancer: when is active surveillance appropriate?

Authors:  Peter C Albertsen
Journal:  Nat Rev Clin Oncol       Date:  2010-05-04       Impact factor: 66.675

Review 8.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

Review 9.  Systematic review of clinical features of suspected prostate cancer in primary care.

Authors:  Sheila-Mae Young; Praveen Bansal; Emily T Vella; Antonio Finelli; Cheryl Levitt; Andrew Loblaw
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

Review 10.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.